– Dr. Davide Molho Appointed to President and Chief Operating Officer
–
– Birgit Girshick Appointed to Corporate Executive Vice President,
Discovery and Safety Assessment –
WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 13, 2018--
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced two new executive management appointments.
Dr. Davide Molho, Corporate Executive Vice President and President,
Global Research Models & Services, Safety Assessment and Biologics, will
become President and Chief Operating Officer of Charles River, effective
immediately, and will add Discovery Services to his responsibilities.
Dr. Molho has a proven track record of outstanding performance, leading
many of the company’s businesses through important strategic initiatives
during his nearly 20 years with Charles River. His extensive operations
management experience in both the United States and Europe uniquely
qualifies Dr. Molho to oversee the company’s global organization and
provide leadership as Charles River continues to grow. Dr. Molho will
continue to report directly to James C. Foster, Chairman and Chief
Executive Officer.
Birgit Girshick, Corporate Senior Vice President, Global Discovery
Services, has been appointed Corporate Executive Vice President,
Discovery and Safety Assessment. During her more than 25 years with the
Company, Ms. Girshick has established an exceptional record of
operational management, most recently leading the global Discovery
business after successfully executing the WIL Research integration.
Realigning management of the Discovery and Safety Assessment businesses
under Ms. Girshick’s leadership will enable Charles River to better
leverage the synergies between the two related units and enhance the
extensive services provided to clients. Ms. Girshick will report
directly to Dr. Molho.
James C. Foster, Chairman and Chief Executive Officer commented, “I look
forward to continuing to work side-by-side with Dr. Molho and Ms.
Girshick as we drive Charles River’s growth and development over the
coming years. We plan to nearly double in size over the course of our
five-year plan, generating significant earnings growth and delivering
value to all our stakeholders, and today’s appointments of Dr. Molho and
Ms. Girshick give us the right leadership structure to support and
advance that plan.”
Management Biographies
Dr. Davide Molho joined Charles River in our Italian operations in 1999
and was promoted to Director of Operations for Research Models and
Services (RMS) Italy in 2002. In 2005, his role was expanded to include
French RMS operations and in 2007, he became Corporate Vice President,
European Research Models and Services, with responsibility for all
European RMS operations. In July 2009, Dr. Molho was promoted to
Corporate Senior Vice President, North American & European Research
Models and Services, and was promoted to Corporate Executive Vice
President and President, Global Research Models and Services in December
2010. Dr. Molho subsequently assumed the role of Corporate Executive
Vice President and President, North American Operations in October 2011
and then Corporate Executive Vice President and President, Global
Research Models & Services, Safety Assessment and Biologics in December
2013. In this role, Dr. Molho was responsible for the global oversight
of these businesses and transitioning to a more fully integrated, global
organizational structure across North America, Europe, and Asia.
Dr. Molho received both his D.V. M. degree and his Post Degree in
Laboratory Animal Science & Medicine from University of Milan.
Birgit Girshick joined Charles River in 1989 and held positions of
increasing responsibility in the Company’s RMS Germany and RMS Avian
Vaccine Services businesses. In 2004, Ms. Girshick was promoted to
General Manager of the RMS Avian Vaccine Services business. She was
named Executive Director, RMS Process Improvement in 2009, and Corporate
Vice President, Global Biopharmaceutical Services in 2010. In 2013, Ms.
Girshick was promoted to Corporate Senior Vice President, Research
Models and Biologics Testing Solutions. In this role, she was
responsible for identifying growth opportunities and managing operations
for the North American Research Models and Global Biologics businesses.
In 2014, Ms. Girshick was tasked with leading the integration of WIL
Research into the Company’s Safety Assessment business. Having
successfully completed the integration, in 2015, Ms. Girshick assumed
the role of Corporate Senior Vice President, Global Discovery Services.
In this role, Ms. Girshick was responsible for transitioning the
discovery business units to a global, integrated organization. As
Corporate Executive Vice President, she becomes a member of the
company’s Executive Committee.
Ms. Girshick received an M.B.A. degree from the University of Rhode
Island and a B.A. degree from Eastern Connecticut State University.
Caution Concerning Forward-Looking Statements
This news release includes forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by the use of words such as “anticipate,”
“believe,” “expect,” “will,” “may,” “estimate,” “plan,” “outlook,” and
“project” and other similar expressions that predict or indicate future
events or trends or that are not statements of historical matters.
Forward-looking statements include statements in this news release
regarding Charles River’s projected future performance, including
revenue and earnings per share growth. Forward-looking statements are
based on Charles River’s current expectations and beliefs, and involve a
number of risks and uncertainties that are difficult to predict and that
could cause actual results to differ materially from those stated or
implied by the forward-looking statements. A further description of
these risks, uncertainties, and other matters can be found in the Risk
Factors detailed in Charles River's Annual Report on Form 10-K as filed
on February 14, 2017, as well as other filings we make with the
Securities and Exchange Commission. Because forward-looking statements
involve risks and uncertainties, actual results and events may differ
materially from results and events currently expected by Charles River,
and Charles River assumes no obligation and expressly disclaims any duty
to update information contained in this news release except as required
by law.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their research
and drug development efforts. Our dedicated employees are focused on
providing clients with exactly what they need to improve and expedite
the discovery, early-stage development and safe manufacture of new
therapies for the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180213005773/en/
Source: Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc.
Investor Contact:
Susan
E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
susan.hardy@crl.com
or
Media
Contact:
Amy Cianciaruso, 781-222-6168
Corporate Vice
President, Public Relations
amy.cianciaruso@crl.com
